Vaccination for atherosclerosis: a novel therapeutic paradigm
(2004) In Expert Review of Vaccines 3(6). p.711-716- Abstract
- Numerous studies have identified a role for the innate and adaptive immune response in atherosclerosis; both pro- and antiatherogenic roles for the immune responses have been demonstrated. Common autoantigens against which an immune response has been identified in experimental and human models of atherosclerosis include oxidized low-density lipopoteins, beta2 glycoprotein 1 and heat shock protein 60. Activation of atheroprotective adaptive immune responses have been demonstrated for oxidized low-density lipoprotein-related antigens. Conversely, atheroprotection has been demonstrated with the induction of immune tolerance through activation of mucosal immunity to heat shock protein 65/60 and beta2 glycoprotein 1. Recent identification of... (More)
- Numerous studies have identified a role for the innate and adaptive immune response in atherosclerosis; both pro- and antiatherogenic roles for the immune responses have been demonstrated. Common autoantigens against which an immune response has been identified in experimental and human models of atherosclerosis include oxidized low-density lipopoteins, beta2 glycoprotein 1 and heat shock protein 60. Activation of atheroprotective adaptive immune responses have been demonstrated for oxidized low-density lipoprotein-related antigens. Conversely, atheroprotection has been demonstrated with the induction of immune tolerance through activation of mucosal immunity to heat shock protein 65/60 and beta2 glycoprotein 1. Recent identification of specific immunoreactive antigenic epitopes in the apolipoprotein B-100 component of low density lipoproetin and early experimental observations have provided proof of concept that active vaccination using specific apolipoprotein B-100-related antigens may emerge as a novel immunomodulating atheroprotective strategy. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1129558
- author
- Shah, Prediman K ; Chyu, Kuang-Yuh ; Fredrikson, Gunilla N and Nilsson, Jan LU
- organization
- publishing date
- 2004
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Expert Review of Vaccines
- volume
- 3
- issue
- 6
- pages
- 711 - 716
- publisher
- Future Drugs Ltd
- external identifiers
-
- pmid:15606356
- scopus:9644302510
- pmid:15606356
- ISSN
- 1744-8395
- DOI
- 10.1586/14760584.3.6.711
- language
- English
- LU publication?
- yes
- id
- 42b0377b-b197-4200-9572-74d51e282531 (old id 1129558)
- date added to LUP
- 2016-04-01 11:45:09
- date last changed
- 2022-01-26 17:40:02
@article{42b0377b-b197-4200-9572-74d51e282531,
abstract = {{Numerous studies have identified a role for the innate and adaptive immune response in atherosclerosis; both pro- and antiatherogenic roles for the immune responses have been demonstrated. Common autoantigens against which an immune response has been identified in experimental and human models of atherosclerosis include oxidized low-density lipopoteins, beta2 glycoprotein 1 and heat shock protein 60. Activation of atheroprotective adaptive immune responses have been demonstrated for oxidized low-density lipoprotein-related antigens. Conversely, atheroprotection has been demonstrated with the induction of immune tolerance through activation of mucosal immunity to heat shock protein 65/60 and beta2 glycoprotein 1. Recent identification of specific immunoreactive antigenic epitopes in the apolipoprotein B-100 component of low density lipoproetin and early experimental observations have provided proof of concept that active vaccination using specific apolipoprotein B-100-related antigens may emerge as a novel immunomodulating atheroprotective strategy.}},
author = {{Shah, Prediman K and Chyu, Kuang-Yuh and Fredrikson, Gunilla N and Nilsson, Jan}},
issn = {{1744-8395}},
language = {{eng}},
number = {{6}},
pages = {{711--716}},
publisher = {{Future Drugs Ltd}},
series = {{Expert Review of Vaccines}},
title = {{Vaccination for atherosclerosis: a novel therapeutic paradigm}},
url = {{http://dx.doi.org/10.1586/14760584.3.6.711}},
doi = {{10.1586/14760584.3.6.711}},
volume = {{3}},
year = {{2004}},
}